Trials / Completed
CompletedNCT04484090
Safety and Efficacy of Ohhmed Treatments for the Improvement of Erectile Dysfunction - A Feasibility Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- OHH-MED Medical Ltd · Industry
- Sex
- Male
- Age
- 40 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
Erectile dysfunction, the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance, is estimated to affect up to 30 million men in the United States. The disorder is age-associated. The available treatments include oral therapy, vacuum-constriction devices; shockwave therapy, intracavernosal injections of vasoactive agents, including alprostadil (prostaglandin E1, transurethral delivery of alprostadil, Implantation of penile prostheses. The OhhMed Company has developed the Vertica device that provides treatments for improvement of erectile function in patients with erectile dysfunction. This study assess the safety, efficacy, ease of use, and satisfaction of the Vertica device by men with mild to moderate erectile dysfunction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Vertica RF device | The treatment provided by the Vertica device is indicated for improving the erectile function in men with erectile dysfunction |
Timeline
- Start date
- 2019-01-20
- Primary completion
- 2021-09-20
- Completion
- 2021-09-20
- First posted
- 2020-07-23
- Last updated
- 2023-01-31
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT04484090. Inclusion in this directory is not an endorsement.